Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
, 96 (16), e6629

350-560 μm Gelatin Sponge Particles Combined With Transcatheter Arterial Chemoembolization for the Treatment of Elderly Hepatocellular Carcinoma: The Safety and Efficacy

Affiliations
Observational Study

350-560 μm Gelatin Sponge Particles Combined With Transcatheter Arterial Chemoembolization for the Treatment of Elderly Hepatocellular Carcinoma: The Safety and Efficacy

Guang Sheng Zhao et al. Medicine (Baltimore).

Abstract

To retrospectively analyze the safety and efficacy of 350-560 μm gelatin sponge particles combined with single-chemotherapy drug transcatheter arterial chemoembolization (Gs-TACE) for the treatment of elderly hepatocellular carcinoma without surgical resection.Thirty elderly hepatocellular carcinoma patients without surgical resection, who received Gs-TACE in our hospital, were selected. Slowly injected gelatin sponge particles (350-560 μm)+ 10 mg lobaplatin injection into the regional embolization tumor target vessel. The Response Evaluation Criteria for Solid Tumors could be used to evaluate the tumor response after intervention surgery.Eighty-nine times of intervention TACE were conducted on the 30 patients. The average size of tumor was 8.3 cm. The median survival time was 28 months, and the 1 and 2-year survival rates were 89% and 58%, respectively. The Response Evaluation Criteria for Solid Tumors was used to evaluate the tumor response, and found that the complete response, partial response, and OR were 30%, 56.67%, and 86.67%, respectively, at 1 month after intervention surgery. The patients were divided into groups: 60 to 65 years age group (A), >65 to 75 years age group (B), and >75 years age group (C); the median survival times were 16, 32, and 33 months, respectively, and there was statistical difference between A group, B group, and C group. The analysis of prognosis factors showed that there was statistical significance in age, Barcelona Clinic Liver Cancer stage, portal vein invasion, and alpha fetal protein (AFP), and age was the protective factor.Gelatin sponge particles (350-560 μm), combined with transcatheter arterial chemoembolization, provide an alternative method for the treatment of elderly hepatocellular carcinoma without surgical resection.

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Kaplan–Meier graph depicting overall survival in the whole cohort (N = 30).
Figure 2
Figure 2
Kaplan–Meier curves for all patients in 3 groups, censored data come from patients who were still alive at the end of the study (group A: 60–65 years age group; group B: >65 to 75 years age group; group C: >75 years ages group).
Figure 3
Figure 3
Computed tomography (CT) image of liver of a 78-year-old patient with primary liver cancer. (A) CT image of liver before surgery; (B) review CT image at 7 days after GS-TACE; (C) review CT image at 1 month after GS-TACE; (D) review CT image at 8 months after GS-TACE; (E) review CT image at 12 months after GS-TACE; CT image after 3-year follow-up.

Similar articles

See all similar articles

Cited by 1 article

References

    1. Bosetti C, Levi F, Boffetta P, et al. Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepatology 2008;48:137–45. - PubMed
    1. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127:S27–34. - PubMed
    1. Kiyosawa K, Umemura T, Ichijo T, et al. Hepatocellular carcinoma: recent trend in Japan. Gastroenterology 2004;127:S17–26. - PubMed
    1. Chen CH, Huang GT, Yang PM, et al. Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. Eur J Cancer 2006;42:2524–9. - PubMed
    1. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010;42Suppl 3:S206–14. - PMC - PubMed

Publication types

MeSH terms

Feedback